Clinical trial results:
A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2009-015019-42
Trial protocol	DE AT BE LT FI Outside EU/EEA
Global end of trial date	27 May 2014

Results information

Result version number	v2 (current)
This version publication date	15 July 2016
First version publication date	29 July 2015
Version creation reason	• Correction of full data set Review of data

Trial information

Trial identification

Sponsor protocol code	CNTO148JIA3001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01230827
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Biologics B.V.
Sponsor organisation address	Archimedesweg 29, Leiden, Netherlands,
Public contact	Clinical Registry Group, Janssen-Cilag International NV, +31 71 524 2166, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen-Cilag International NV, +31 71 524 2166, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000265-PIP01-08
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 May 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	27 May 2014
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to assess the clinical efficacy of subcutaneous (SC) administration of golimumab in pediatric subjects (ages 2 to less than [<]18 years) with polyarticular juvenile idiopathic arthritis (pJIA) manifested by more than equal to (>=)5 joints with active arthritis despite methotrexate (MTX) therapy for >=3 months.

Protection of trial subjects:

In this study, safety evaluations included monitoring of adverse events (AEs), clinical laboratory tests, vital sign measurements and injection-site reaction evaluations. Tuberculosis evaluations, including QuantiFERON-TB Gold test and Mantoux tuberculin skin test were performed. Serum samples for the determination of the presence of antinuclear antibodies/anti-double-stranded DNA antibodies were also collected.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 December 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 5
Country: Number of subjects enrolled	Belgium: 10
Country: Number of subjects enrolled	Brazil: 8
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Germany: 49
Country: Number of subjects enrolled	Finland: 1
Country: Number of subjects enrolled	Lithuania: 10
Country: Number of subjects enrolled	Mexico: 22
Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Poland: 7
Country: Number of subjects enrolled	Russian Federation: 29
Country: Number of subjects enrolled	United States: 21
Worldwide total number of subjects	173
EEA total number of subjects	86

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	83
Adolescents (12-17 years)	90
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted between 01 December 2010 to 27 May 2014 and 173 subjects were enrolled in the study.

Pre-assignment

Screening details:

In this study, 173 enrolled subjects received golimumab 30 milligram per square meter (mg/m^2) + MTX at Week 0. A total of 154 subjects were randomized to treatment at Week 16; 76 were randomized to receive placebo + MTX and 78 were randomized to receive golimumab 30 mg/m^2 + methotrexate (MTX).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Group I: Enrolled subjects who did not enter RW period

Arm description:

Enrolled subjects who did not enter randomized withdrawal period, including those who discontinued prior Week 16, and those who were non-responders (did not achieve an ACR Ped 30 response) at Week 16.

Arm type	Experimental
Investigational medicinal product name	Golimumab
Investigational medicinal product code	CNTO148
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Enrolled subjects who did not enter randomized withdrawal period, including those who discontinued prior Week 16, and those who were non-responders (did not achieve an ACR Ped 30 response) at Week 16.

Arm title	Group II: Placebo SC + MTX

Arm description:

Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).

Investigational medicinal product name	Methotrexate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).

Arm title	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX

Arm description:

Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).

Arm type	Placebo
Investigational medicinal product name	Golimumab
Investigational medicinal product code	CNTO148
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).

Investigational medicinal product name	Methotrextae
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).

Arm title	Group IV: Golimumab + MTX

Arm description:

Subjects were treated with golimumab 30 mg/m^2 through Week 12 and who were treated with golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).

Arm type	Experimental
Investigational medicinal product name	Golimumab
Investigational medicinal product code	CNTO148
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were treated with golimumab 30 mg/m^2 through Week 12 and who were treated with golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).

Investigational medicinal product name	Methotrexate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were treated with golimumab 30 mg/m^2 through Week 12 and who were treated with

golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).

Number of subjects in period 1	Group I: Enrolled subjects who did not enter RW period	Group II: Placebo SC + MTX	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX
Started	19	11	65
Completed	0	0	0
Not completed	19	11	65
Consent withdrawn by subject	1	-	3
Recovery	-	6	-
Adverse event	4	2	3
Study terminated by sponsor	-	2	56
Lost to follow-up	-	-	1
Lack of efficacy	14	1	2

Number of subjects in period 1	Group IV: Golimumab + MTX
Started	78
Completed	0
Not completed	78
Consent withdrawn by subject	2
Recovery	-
Adverse event	7
Study terminated by sponsor	63
Lost to follow-up	3
Lack of efficacy	3

Baseline characteristics

Reporting groups	
Reporting group title	Group I: Enrolled subjects who did not enter RW period
Reporting group description:	
Enrolled subjects who did not enter randomized withdrawal period, including those who discontinued prior Week 16, and those who were non-responders (did not achieve an ACR Ped 30 response) at Week 16.	
Reporting group title	Group II: Placebo SC + MTX
Reporting group description:	
Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).	
Reporting group title	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX
Reporting group description:	
Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).	
Reporting group title	Group IV: Golimumab + MTX
Reporting group description:	
Subjects were treated with golimumab 30 mg/m^2 through Week 12 and who were treated with golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).	

Reporting group values	Group I: Enrolled subjects who did not enter RW period	Group II: Placebo SC + MTX	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX
Number of subjects	19	11	65
Title for AgeCategorical			
Units: subjects			
Children (2-11 years)	8	2	34
Adolescents (12-17 years)	11	9	31
Adults (18-64 years)	0	0	0
From 65 to 84 years	0	0	0
85 years and over	0	0	0
Title for AgeContinuous			
Units: years			
arithmetic mean	11.8	13.6	10.7
standard deviation	± 4.4	± 2.2	± 4.66
Title for Gender			
Units: subjects			
Female	15	6	51
Male	4	5	14

Reporting group values	Group IV: Golimumab + MTX	Total	
Number of subjects	78	173	
Title for AgeCategorical			
Units: subjects			
Children (2-11 years)	39	83	
Adolescents (12-17 years)	39	90	
Adults (18-64 years)	0	0	
From 65 to 84 years	0	0	

85 years and over	0	0	

Title for AgeContinuous Units: years			
arithmetic mean	11.1		
standard deviation	± 4.43	-	
Title for Gender Units: subjects			
Female	59	131	
Male	19	42	

End points

End points reporting groups

Reporting group title	Group I: Enrolled subjects who did not enter RW period

Reporting group description:

Enrolled subjects who did not enter randomized withdrawal period, including those who discontinued prior Week 16, and those who were non-responders (did not achieve an ACR Ped 30 response) at Week 16.

Reporting group title	Group II: Placebo SC + MTX

Reporting group description:

Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).

Reporting group title	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX

Reporting group description:

Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).

Reporting group title	Group IV: Golimumab + MTX

Reporting group description:

Subjects were treated with golimumab 30 mg/m^2 through Week 12 and who were treated with golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).

Subject analysis set title	Participants Allocated to Placebo
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Intent-to-treat (ITT) population included all participants achieving American College of Rheumatology (ACR) Pediatric (Ped) 30 response who were randomized at Week 16.

Subject analysis set title	Participants Allocated to Golimumab
Subject analysis set type	Intention-to-treat

Subject analysis set description:

ITT population included all participants achieving American College of Rheumatology (ACR) Pediatric (Ped) 30 response who were randomized at Week 16.

Primary: Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48

End point title	Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48

End point description:

Percentage of participants with ACR Ped 30 responders at Week 16 who did not experience a flare of disease between Week 16 and Week 48 calculated as number of participants with response and who did not experience flare divided by number of participants randomized. Flare of disease was defined as the worsening from Week 16 by 30% or more in 3 of the 6 ACR Ped Core Set Variables with no more than 1 of the 6 ACR Ped Core Set variables improving by more than 30% at the time of the flare. The 6 variables are: physicians global assessment of disease, participants/parent global assessment of overall well-being, number of active joints (defined as either swelling, limited range of motion associated with pain on motion or tenderness), number of joints with limited range of motion, physical function by childhood health assessment questionnaire, and erythrocyte sedimentation rate. ITT population included all participants achieving ACR Ped 30 response who were randomized at Week 16.

End point type	Primary

End point timeframe:

Week 16 through Week 48

End point values	Participants Allocated to Placebo	Participants Allocated to Golimumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	76	78		
Units: percentage of participants				
number (not applicable)	52.6	59		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Participants Allocated to Placebo v Participants Allocated to Golimumab
Number of subjects included in analysis	154
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.414
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response at Week 48

End point title	Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response at Week 48

End point description:

Percentage of participants with ACR Ped 30 response at Week 48 was calculated as number of participants with ACR 30 response at Week 48 divided by number of participants randomized. ACR Ped 30 response was defined as the worsening from Week 16 by 30% or more in 3 of the 6 ACR Pediatric (Ped) Core Set Variables with no more than 1 of the 6 ACR Ped Core Set variables improving by more than 30% at the time of the flare. The 6 variables are: physicians global assessment of disease, participants/parent global assessment of overall well-being, number of active joints (defined as either swelling, or in absence of swelling, limited range of motion associated with pain on motion or tenderness), number of joints with limited range of motion, physical function by childhood health assessment questionnaire and erythrocyte sedimentation rate. ITT population included all participants achieving ACR Ped 30 response who were randomized at Week 16.

End point type	Secondary

End point timeframe:

Week 16 through Week 48

End point values	Participants Allocated to Placebo	Participants Allocated to Golimumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	76	78		
Units: percentage of participants				
number (not applicable)	55.3	52.6		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Participants Allocated to Placebo v Participants Allocated to Golimumab
Number of subjects included in analysis	154
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.751
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response Who Had Inactive Disease at Week 48

End point title	Percentage of Participants With American College of Rheumatology (ACR Ped) 30 Response Who Had Inactive Disease at Week 48

End point description:

Inactive disease is indicated by the presence of all of the following: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly or generalized lymphadenopathy attributable to juvenile idiopathic arthritis; normal erythrocyte sedimentation rate or C-reactive protein, no active uveitis (eye disease); physician global assessment of disease activity indicating no active disease; and duration of morning stiffness less than 15 minutes. ITT population included all participants achieving ACR Ped 30 response who were randomized at Week 16.

End point type	Secondary

End point timeframe:

Week 16 through Week 48

End point values	Participants Allocated to Placebo	Participants Allocated to Golimumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	76	78		
Units: Percentage of Participants				
number (not applicable)	27.6	39.7		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Participants Allocated to Placebo v Participants Allocated to Golimumab
Number of subjects included in analysis	154
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.119
Method	Cochran-Mantel-Haenszel

Secondary: Percentage of Participants Who Achieved Clinical Remission While on Medication for Juvenile Idiopathic Arthritis (JIA) at Week 48

End point title	Percentage of Participants Who Achieved Clinical Remission While on Medication for Juvenile Idiopathic Arthritis (JIA) at Week 48

End point description:

Clinical remission while on medication for JIA is defined as inactive disease at each visit for a period of 6 months or more while on medication. Inactive disease is indicated by the presence of all of the following: no joints with active arthritis; no fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to juvenile idiopathic arthritis; no active uveitis (eye disease), normal erythrocyte sedimentation rate or C-reactive protein; physician global assessment of disease activity indicating no active disease; and duration of morning stiffness less than 15 minutes. ITT population included all participants achieving ACR Ped 30 response who were randomized at Week 16.

End point type	Secondary

End point timeframe:

Week 16 through Week 48

End point values	Participants Allocated to Placebo	Participants Allocated to Golimumab		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	76	78		
Units: percentage of participants				
number (not applicable)	11.8	12.8		

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Participants Allocated to Golimumab v Participants Allocated to Placebo
Number of subjects included in analysis	154
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.848
Method	Cochran-Mantel-Haenszel

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 up to Database Lock (DBL) (approximately Week 184)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

Reporting groups

Reporting group title	Group I: Enrolled subjects who did not enter RW period

Reporting group description:

Enrolled subjects who did not enter randomized withdrawal period, including those who discontinued prior Week 16, and those who were non-responders (did not achieve an ACR Ped 30 response) at Week 16.

Reporting group title	Group II: Placebo SC + MTX

Reporting group description:

Subjects who were treated with golimumab 30 milligram per square meter (mg/m^2) through Week 12 and were treated with placebo + MTX at Week 16 and continued on placebo + MTX after Week 48 through the final DBL (Data Base Lock).

Reporting group title	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX

Reporting group description:

Subjects who were treated with golimumab 30 mg/m^2 through Week 12 and were treated with placebo + MTX at Week 16 and switched to golimumab 30 mg/m^2 + MTX at anytime during the study after Week 48 through the final DBL (Data Base Lock).

Reporting group title	Group IV: Golimumab + MTX

Reporting group description:

Subjectswere treated with golimumab 30 mg/m^2 through Week 12 and who were treated with golimumab 30 mg/m^2 + MTX at Week 16 and continued on golimumab 30 mg/m^2 + MTX after Week 48 through the final DBL (Data Base Lock).

Serious adverse events	Group I: Enrolled subjects who did not enter RW period	Group II: Placebo SC + MTX	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 19 (21.05%)	2 / 10 (20.00%)	15 / 66 (22.73%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			

subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Tonsillar hypertrophy			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somatoform disorder neurologic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lower limb fracture			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Demyelination			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Immune thrombocytopenic purpura			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoid tissue hyperplasia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Eye pain			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Gallbladder oedema			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis toxic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Juvenile idiopathic arthritis			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	6 / 66 (9.09%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendiceal abscess			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scarlet fever			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin bacterial infection			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Group IV: Golimumab + MTX		
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 78 (23.08%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			

subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Tonsillar hypertrophy			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Somatoform disorder neurologic			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Lower limb fracture			

subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Demyelination			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Immune thrombocytopenic purpura			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphoid tissue hyperplasia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Eye pain			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis			

subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Gallbladder oedema			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis toxic			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Arthritis			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Juvenile idiopathic arthritis			
subjects affected / exposed	8 / 78 (10.26%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendiceal abscess			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Cellulitis			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Herpes zoster			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Otitis media			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Scarlet fever			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Skin bacterial infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			

subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Group I: Enrolled subjects who did not enter RW period	Group II: Placebo SC + MTX	Group III: Placebo + MTX -> Golimumab 30 mg/m^2 + MTX
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 19 (73.68%)	9 / 10 (90.00%)	60 / 66 (90.91%)
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Influenza like illness			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	8 / 66 (12.12%)
occurrences (all)	0	0	8
Injection site reaction			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences (all)	0	1	1
Pyrexia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	15 / 66 (22.73%)
occurrences (all)	0	0	24
Serositis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	3 / 66 (4.55%)
occurrences (all)	1	0	6
Dyspnoea			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	2 / 66 (3.03%)
occurrences (all)	1	0	2
Oropharyngeal pain			
subjects affected / exposed	1 / 19 (5.26%)	2 / 10 (20.00%)	7 / 66 (10.61%)
occurrences (all)	1	2	11
Rhinorrhoea			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	3
Upper respiratory tract congestion			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			

Affective disorder			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Emotional distress			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Sleep disorder			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	3 / 66 (4.55%)
occurrences (all)	1	0	3
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
C-reactive protein increased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	3 / 66 (4.55%)
occurrences (all)	0	1	4
Neutrophil count increased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Transaminases increased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Weight decreased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
White blood cell count increased			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			

Arthropod sting			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Clavicle fracture			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Contusion			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	3 / 66 (4.55%)
occurrences (all)	1	0	3
Foot fracture			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences (all)	0	1	1
Ligament sprain			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	2 / 66 (3.03%)
occurrences (all)	0	1	3
Injury			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Traumatic fracture			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	10 / 66 (15.15%)
occurrences (all)	1	0	20
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	0	0	4
Eye disorders			

Conjunctivitis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	5 / 66 (7.58%)
occurrences (all)	1	0	7
Erythema of eyelid			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Eyelid oedema			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 19 (0.00%)	2 / 10 (20.00%)	8 / 66 (12.12%)
occurrences (all)	0	3	11
Abdominal pain upper			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	10 / 66 (15.15%)
occurrences (all)	0	0	13
Aphthous stomatitis			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	4 / 66 (6.06%)
occurrences (all)	0	1	5
Constipation			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	5 / 66 (7.58%)
occurrences (all)	0	0	5
Diarrhoea			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	9 / 66 (13.64%)
occurrences (all)	0	0	16
Dental caries			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Nausea			

subjects affected / exposed	2 / 19 (10.53%)	2 / 10 (20.00%)	7 / 66 (10.61%)
occurrences (all)	2	3	8
Peptic ulcer			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	13 / 66 (19.70%)
occurrences (all)	0	0	18
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	3 / 66 (4.55%)
occurrences (all)	1	1	4
Alopecia			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Dermatitis atopic			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
Eczema			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences (all)	0	1	2
Urticaria			
subjects affected / exposed	2 / 19 (10.53%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	2	0	4
Rash generalised			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	6 / 66 (9.09%)
occurrences (all)	0	2	6
Arthritis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	2 / 66 (3.03%)
occurrences (all)	1	0	2
Foot deformity			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	2 / 66 (3.03%)
occurrences (all)	0	1	2
Juvenile idiopathic arthritis			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	11 / 66 (16.67%)
occurrences (all)	2	1	12
Muscle spasms			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences (all)	0	1	1
Pain in extremity			
subjects affected / exposed	1 / 19 (5.26%)	1 / 10 (10.00%)	3 / 66 (4.55%)
occurrences (all)	1	2	3
Synovitis			
subjects affected / exposed	0 / 19 (0.00%)	2 / 10 (20.00%)	1 / 66 (1.52%)
occurrences (all)	0	2	1
Tenosynovitis			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Tendon pain			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	1	0	4
Acute tonsillitis			

subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	3 / 66 (4.55%)
occurrences (all)	0	1	5
Gastroenteritis			
subjects affected / exposed	2 / 19 (10.53%)	1 / 10 (10.00%)	6 / 66 (9.09%)
occurrences (all)	3	1	6
Gastroenteritis viral			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	6 / 66 (9.09%)
occurrences (all)	0	0	6
Gingivitis			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	1 / 66 (1.52%)
occurrences (all)	0	1	1
Influenza			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	2 / 66 (3.03%)
occurrences (all)	0	0	2
Laryngitis			
subjects affected / exposed	0 / 19 (0.00%)	1 / 10 (10.00%)	0 / 66 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	2 / 19 (10.53%)	3 / 10 (30.00%)	18 / 66 (27.27%)
occurrences (all)	2	3	39
Otitis media			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	5 / 66 (7.58%)
occurrences (all)	0	0	9
Paronychia			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	2 / 66 (3.03%)
occurrences (all)	1	0	2
Pharyngitis			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	6 / 66 (9.09%)
occurrences (all)	0	0	7
Pharyngitis streptococcal			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection			

subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	9 / 66 (13.64%)
occurrences (all)	1	0	13
Respiratory tract infection viral			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	0	0	4
Rhinitis			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	0	0	10
Sinusitis			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	7 / 66 (10.61%)
occurrences (all)	0	0	8
Tonsillitis			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	6 / 66 (9.09%)
occurrences (all)	0	0	8
Upper respiratory tract infection			
subjects affected / exposed	1 / 19 (5.26%)	3 / 10 (30.00%)	25 / 66 (37.88%)
occurrences (all)	1	4	47
Urinary tract infection			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	1 / 66 (1.52%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	0 / 19 (0.00%)	0 / 10 (0.00%)	4 / 66 (6.06%)
occurrences (all)	0	0	6
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 19 (5.26%)	0 / 10 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Group IV: Golimumab + MTX		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	68 / 78 (87.18%)		
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Influenza like illness			

subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	9 / 78 (11.54%)		
occurrences (all)	10		
Serositis			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	10 / 78 (12.82%)		
occurrences (all)	14		
Dyspnoea			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Oropharyngeal pain			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Rhinorrhoea			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Upper respiratory tract congestion			

subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	3		
Psychiatric disorders			
Affective disorder			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Emotional distress			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Sleep disorder			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	8 / 78 (10.26%)		
occurrences (all)	9		
Aspartate aminotransferase increased			
subjects affected / exposed	7 / 78 (8.97%)		
occurrences (all)	8		
C-reactive protein increased			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	3		
Hepatic enzyme increased			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Neutrophil count increased			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Transaminases increased			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
White blood cell count increased			

subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Arthropod sting			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Clavicle fracture			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	2		
Foot fracture			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Ligament sprain			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Injury			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Traumatic fracture			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	15 / 78 (19.23%)		
occurrences (all)	21		
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	5		

Neutropenia			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Eye disorders			
Conjunctivitis			
subjects affected / exposed	7 / 78 (8.97%)		
occurrences (all)	13		
Erythema of eyelid			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Eyelid oedema			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	7 / 78 (8.97%)		
occurrences (all)	8		
Abdominal pain upper			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	3		
Aphthous stomatitis			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Diarrhoea			
subjects affected / exposed	7 / 78 (8.97%)		
occurrences (all)	9		
Dental caries			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Haemorrhoids			

subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	11 / 78 (14.10%)		
occurrences (all)	12		
Peptic ulcer			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	12 / 78 (15.38%)		
occurrences (all)	15		
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Alopecia			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Dermatitis atopic			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	5		
Eczema			
subjects affected / exposed	4 / 78 (5.13%)		
occurrences (all)	4		
Pruritus			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	8		
Rash generalised			

subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	4		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	8 / 78 (10.26%)		
occurrences (all)	9		
Arthritis			
subjects affected / exposed	3 / 78 (3.85%)		
occurrences (all)	8		
Foot deformity			
subjects affected / exposed	2 / 78 (2.56%)		
occurrences (all)	2		
Back pain			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Juvenile idiopathic arthritis			
subjects affected / exposed	18 / 78 (23.08%)		
occurrences (all)	27		
Muscle spasms			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	6 / 78 (7.69%)		
occurrences (all)	6		
Synovitis			
subjects affected / exposed	1 / 78 (1.28%)		
occurrences (all)	1		
Tenosynovitis			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Tendon pain			
subjects affected / exposed	0 / 78 (0.00%)		
occurrences (all)	0		
Infections and infestations			

Bronchitis				
subjects affected / exposed	6 / 78 (7.69%)			
occurrences (all)	10			
Acute tonsillitis				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Gastroenteritis				
subjects affected / exposed	8 / 78 (10.26%)			
occurrences (all)	10			
Gastroenteritis viral				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Gingivitis				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Herpes zoster				
subjects affected / exposed	0 / 78 (0.00%)			
occurrences (all)	0			
Influenza				
subjects affected / exposed	7 / 78 (8.97%)			
occurrences (all)	10			
Laryngitis				
subjects affected / exposed	2 / 78 (2.56%)			
occurrences (all)	2			
Nasopharyngitis				
subjects affected / exposed	21 / 78 (26.92%)			
occurrences (all)	35			
Otitis media				
subjects affected / exposed	6 / 78 (7.69%)			
occurrences (all)	12			
Paronychia				
subjects affected / exposed	1 / 78 (1.28%)			
occurrences (all)	1			
Pharyngitis				
subjects affected / exposed	9 / 78 (11.54%)			
occurrences (all)	10			

Pharyngitis streptococcal subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		
Respiratory tract infection subjects affected / exposed occurrences (all)	10 / 78 (12.82%) 14		
Respiratory tract infection viral subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 3		
Rhinitis subjects affected / exposed occurrences (all)	10 / 78 (12.82%) 15		
Sinusitis subjects affected / exposed occurrences (all)	8 / 78 (10.26%) 10		
Tonsillitis subjects affected / exposed occurrences (all)	8 / 78 (10.26%) 12		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	20 / 78 (25.64%) 46		
Urinary tract infection subjects affected / exposed occurrences (all)	4 / 78 (5.13%) 4		
Viral infection subjects affected / exposed occurrences (all)	2 / 78 (2.56%) 2		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	1 / 78 (1.28%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 April 2010	The first amendment included the following changes: 1) At the time of the Week 48 database lock (DBL) subjects randomized to placebo who were not in clinical remission began receiving golimumab 30 mg/m^2 SC and subjects randomized to placebo who were already in clinical remission, were discontinued from the study; 2) only the 1 milliliter (mL) single-use prefilled syringe (PFS) for SC administration was supplied and not the 0.5 mL PFS containing 50 mg of golimumab; 3) text was clarified to indicate that the determination of flare of disease (according to JIA pediatric criteria for flare) was based on comparison of criteria with Week 16 values; 4) a change from independent joint assessor (IJA) to consistent joint assessor was necessary as the Sponsor was unable to obtain IJAs for all sites in a timely manner.
10 June 2010	The second amendment included that the total maximum blood volume (mL) to be collected from each subject per visit was appropriately adjusted for a 2.5 mL serum separator tube due to the lack of availability of 2.0 mL serum separator tubes.
03 August 2010	The third amendment included the following key changes: The consistent joint assessor's responsibilities were clarified.
28 October 2010	The fourth amendment included the following key changes: 1) Routine laboratory analyses and ESR evaluations were rescheduled; 2) ESR evaluations, routine laboratory analyses and QuantiFERON Gold TB tests were rescheduled; 3) amended description of interim analyses (Response at Week 8); 4) revised inclusion criteria for the use of MTX (dosage), immunizations, and previous use of anti-TNFα agents, and clarified TB screening criteria; 5) revised exclusion criteria for chest radiographs and history of hepatitis B infection, and added additional exclusion criteria for hepatitis B testing and the use of anti-TNFα agents; 6) the use of MTX (dosage) during the course of the study was clarified and added additional text regarding the use of intramuscular administration of corticosteroids; 7) revised total blood volume to be collected; 8) clarified inactive diseases and added serum hepatitis B virus testing; 9) revised statistical rules for the determination of treatment failures.
23 November 2010	The fifth amendment included the following key changes: 1) The numbering for inclusion criterion 8 was revised. Inclusion criterion 26 was deleted, but the content was retained under criterion 20c; 2) revised the total blood volume to be collected.
07 March 2011	The sixth amendment included the following key changes: 1) Revised the chest x-ray schedule from Week 108 to Week 104 to correct an inadvertent check mark 2) text was added to indicate how concomitant medication would be adjusted for subjects with a worsening of clinical status between Weeks 0 and 16; 3) the sponsor clarified that golimumab dose would be adjusted by BSA for each subject for all q4w doses and also clarified that golimumab dose decreases or increases below or above 30 mg/m^2 based upon BSA will not be permitted; 4) listed the evaluations to be performed and the forms that need to be filled at every unscheduled visit; 5) subjects who developed study agent-related bronchospasm requiring bronchodilator treatment were to be permanently discontinued from further treatment with study agent; 6) clarified evaluation of uveitis; 7) clarified efficacy evaluations conducted at all times and at screening.

31 May 2012	The seventh amendment included the following changes: 1) The name of the sponsor for this protocol was changed to Janssen Research & Development; 2) added clarification of the minimum weekly dosage of MTX for subjects who were ≥1.67 m^2; 3) made clarification on the use of corticosteroids and MTX after Week 16 or in the event of a flare; 4) the number of joints to be evaluated was revised to include subtalar joints (1 in each foot) on the advice of the Pediatric Rheumatology International Trials Organisation/Pediatric Rheumatology Collaborative Study Group; 5) subjects were to be observed for at least 30 minutes after the SC administration of study agent for symptoms of injection-site reaction; 6) corrections were made to the PK sampling schedule for consistency; 7) The Annual Safety Report was replaced by the Development Safety Update Report per Health Authority direction; 8) subjects were identified by subject ID and date of birth in addition to anonymous initials.
20 February 2013	The eighth amendment included the following key changes: 1) The use of DMARDs, corticosteroids, and NSAIDs between Weeks 16 and 48 was clarified; 2) the weekly commercial MTX dosage to be administered was clarified.
18 June 2013	The ninth amendment included the following key changes: 1) The long-term extension of this study was extended by 104 weeks; 2) updated the total volume of blood to be collected; 3) updated the list regarding inactive disease was updated; 4) minor editorial changes were made.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
27 May 2014	Trial was discontinued since the primary and major secondary endpoints were not met.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was planned to continue to Week 256; however, the primary and major secondary efficacy endpoints at Week 48 were not met and the sponsor decided to discontinue the study prematurely.

Notes: